PanGen Biotech Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Public

  • Employees
  • 75

Employees

  • Stock Symbol
  • 222110

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $3.00
  • (As of Friday Closing)

PanGen Biotech General Information

Description

Pangen Biotech Inc is a biotechnology company. The company is engaged in the production and sales of biosimilar EPO drugs, contract manufacturing (CMO), and development technology transfer service (CDO) business for biopharmaceuticals, including non-clinical and clinical samples, and biopharmaceutical development business.

Contact Information

Website
www.pangen.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Woncheon-dong, 4 Floor Innoplex 2-dong 306
  • Sinwon-ro, Yeongtong-gu
  • Suwon, Gyeonggi 16675
  • South Korea
+82
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Stock Exchange
KRX
Corporate Office
  • Woncheon-dong, 4 Floor Innoplex 2-dong 306
  • Sinwon-ro, Yeongtong-gu
  • Suwon, Gyeonggi 16675
  • South Korea
+82

PanGen Biotech Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

PanGen Biotech Stock Performance

As of 13-Nov-2026, PanGen Biotech’s stock price is $3.00. Its current market cap is $40.6M with 13.5M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$3.00 $2.99 $2.59 - $5.77 $40.6M 13.5M 6.56K $0.06

PanGen Biotech Financials Summary

As of 30-Jun-2026, PanGen Biotech has a trailing 12-month revenue of $9.8M.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 34,723 43,996 46,314 57,657
Revenue 9,769 9,428 10,754 5,595
EBITDA 1,650 2,286 1,912 (2,039)
Net Income 780 1,441 692 (3,433)
Total Assets 21,567 22,708 20,737 16,095
Total Debt 5 668 556 1,566
Public Fundamental Data provided by Morningstar, Inc. disclaimer

PanGen Biotech Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore PanGen Biotech‘s full profile, request access.

Request a free trial

PanGen Biotech Patents

PanGen Biotech Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260014088-A1 Lipid nanoparticles for protein delivery Pending 15-Jul-2022
WO-2024014928-A1 Lipid nanoparticles for protein delivery Inactive 15-Jul-2022
EP-4186492-A1 Ophthalmic liquid composition Active 24-Jul-2020
EP-4186492-A4 Ophthalmic liquid composition Active 24-Jul-2020
EP-4186492-B1 Ophthalmic liquid composition Active 24-Jul-2020 A61K9/08
To view PanGen Biotech’s complete patent history, request access »

PanGen Biotech Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

PanGen Biotech Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore PanGen Biotech‘s full profile, request access.

Request a free trial

PanGen Biotech Investments (1)

PanGen Biotech’s most recent deal was a Joint Venture with Biosimilar Production Facility (Duopharma Biotech Berhad / PanGen Biotech / VentureTECH Sdn Bhd). The deal was made on 17-Jul-2020.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Biosimilar Production Facility (Duopharma Biotech Berhad / PanGen Biotech / VentureTECH Sdn Bhd) 17-Jul-2020 Joint Venture Pharmaceuticals
To view PanGen Biotech’s complete investments history, request access »

PanGen Biotech ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view PanGen Biotech’s complete esg history, request access »

PanGen Biotech FAQs

  • When was PanGen Biotech founded?

    PanGen Biotech was founded in 2010.

  • Where is PanGen Biotech headquartered?

    PanGen Biotech is headquartered in Suwon, South Korea.

  • What is the size of PanGen Biotech?

    PanGen Biotech has 75 total employees.

  • What industry is PanGen Biotech in?

    PanGen Biotech’s primary industry is Pharmaceuticals.

  • Is PanGen Biotech a private or public company?

    PanGen Biotech is a Public company.

  • What is PanGen Biotech’s stock symbol?

    The ticker symbol for PanGen Biotech is 222110.

  • What is the current stock price of PanGen Biotech?

    As of 13-Nov-2026 the stock price of PanGen Biotech is $3.00.

  • What is the current market cap of PanGen Biotech?

    The current market capitalization of PanGen Biotech is $40.6M.

  • What is PanGen Biotech’s current revenue?

    The trailing twelve month revenue for PanGen Biotech is $9.8M.

  • What is PanGen Biotech’s annual earnings per share (EPS)?

    PanGen Biotech’s EPS for 12 months was $0.06.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process